Trial Profile
A Study to evaluate the immunomodulatory effects of natalizumab in patients with multiple sclerosis (MS).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Nov 2015
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 16 Nov 2015 New trial record